Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma

Sponsor
Hellenic Cooperative Oncology Group
Study ID
NCT01264341
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Bevacizumab 10mg/kg intravenous every 2 weeks until disease progression, unacceptable toxicity or consent withdrawal.
  • Temsirolimus — DRUG
    Temsirolimus 25mg intravenous once weekly until disease progression, unacceptable toxicity or consent withdrawal.

Study Details

The purpose of this study is to determine whether the combination of bevacizumab/temsirolimus is effective in patients with advanced renal carcinoma progressing after anti-VEGF treatment

Key Dates

First listed
Dec 21, 2010
Start date
Dec 31, 2010
Status verified
Feb 2017
Primary completion
Jul 31, 2015
Completion
Jul 31, 2015

Study Design

Enrollment
39 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab combined with temsirolimus
    Bevacizumab 10mg/kg intravenous every 2 weeks Temsirolimus 25mg intravenous once weekly

Primary Outcome Measure

6-month Progression Free Survival (PFS) [ Time Frame: 32 months ]

Related Studies